Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DREAMM-7 belantamab mafodotin + bortezomib + dexamethasone versus daratumumab + bortezomib + dexamethasone in relapsed/refractory multiple myeloma
MOH_2020-07-05_009113Phase 3Not yet recruiting
- Sponsor
- GSK
- Start
- Jun 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in multiple myeloma (MM) comparing Arm A: belantamab mafodotin + bortezomib + dexamethasone with Arm B: daratumumab + bortezomib + dexamethasone (2 arms). Planned start Jun 2020; status: not yet recruiting.
02
Drugs
belantamab mafodotindaratumumabbortezomibdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on MOH_2020-07-05_009113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-07-05_009113.